表紙
市場調査レポート

アジア太平洋地域の2型糖尿病治療薬市場:新規薬物クラスの取り込み増大が市場成長を促進

Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

発行 GBI Research 商品コード 320686
出版日 ページ情報 英文 107 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
アジア太平洋地域の2型糖尿病治療薬市場:新規薬物クラスの取り込み増大が市場成長を促進 Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth
出版日: 2014年11月30日 ページ情報: 英文 107 Pages
概要

アジア太平洋地域の2型糖尿病治療薬市場は、2013年の65億米ドルから、2020年には105億米ドル規模まで拡大し、CAGRで7.1%の成長が予測されています。

当レポートでは、アジア太平洋地域の2型糖尿病治療薬市場について調査分析し、市場の概要、上市製品、パイプライン製品、市場予測、取引と戦略的統合などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 症状
  • 病因
  • 病態生理学
  • 診断
  • 疫学
  • 予後
  • 併存疾患や合併症
  • 治療と管理

第3章 上市製品

  • メトホルミン
  • DPP-4阻害薬
  • GLP-1作動薬
  • スルホニル尿素
  • チアゾリジンジオン
  • 持続型インスリン
  • SGLT阻害薬
  • 有効性と安全性の比較

第4章 パイプライン製品

  • パイプライン全体
  • パイプライン分析:分子タイプ別
  • パイプライン分析:作用機序別
  • 臨床試験
  • パイプラインにおける有望薬の候補
    • LY-2189265 (dulaglutide)
    • Albiglutide
    • Ipragliflozin
    • Semaglutide

第5章 市場予測

  • 地域別市場
    • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
  • 市場促進要因と障壁
    • 促進要因
    • 障壁

第6章 取引と戦略的統合

  • 主なライセンス取引
  • 主な共同開発取引

第7章 付録

図表

目次

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth", which provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.

In 2013, the value of the type 2 diabetes therapeutics market in APAC countries was an estimated $6.5 billion, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.1% between 2013 and 2020 to $10.5 billion. This strong growth is due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, and Sodium Glucose Transporter-2 (SGLT-2) inhibitors, as well as the growth of the prevalence population in the APAC region, particularly in India and China.

Scope

The report analyzes the treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals of the type 2 diabetes in the APAC markets of China, India, Japan, and Australia.It includes -

  • A brief introduction to type 2 diabetes, including its pathophysiology, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for type 2 diabetes, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy
  • A comprehensive review of the pipeline for type 2 diabetes, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed by Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario market forecast data to 2020, taking into account how the market might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the type 2 diabetes market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to -

  • Understand the type 2 diabetes pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles for promising pipeline products and gain an insight into how and with whom they are likely to compete in the market
  • Follow the trends in type 2 diabetes clinical trial size and duration in relation to industry averages
  • Assess the potential risk of future developmental programs for type 2 diabetes therapeutics, depending on the mechanism of action, by taking into account the recorded clinical trial failure rates
  • Examine the growth patterns expected for the type 2 diabetes market over the forecast period and the countries that are expected to contribute the most to this growth, allowing you to devise a more effectively tailored country strategy through an understanding of key drivers and barriers
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Symptoms
  • 2.2. Etiology
  • 2.3. Pathophysiology
  • 2.4. Diagnosis
  • 2.5. Epidemiology
  • 2.6. Prognosis
  • 2.7. Co-Morbidities and Complications
  • 2.8. Treatment and Management
    • 2.8.1. The Role of Insulin in Type 2 Diabetes
    • 2.8.2. Non-Insulin Diabetic Drugs
    • 2.8.3. Other Drugs

3. Marketed Products

  • 3.1. Metformin
  • 3.2. DPP-4 Inhibitors
    • 3.2.1. Januvia (sitagliptin)/Janumet (sitagliptin and metformin), Merck
    • 3.2.2. Tradjenta (linagliptin) - Boehringer Ingelheim
    • 3.2.3. Onglyza (saxagliptin) - Bristol-Myers Squibb and AstraZeneca
    • 3.2.4. Nesina (alogliptin) - Takeda
    • 3.2.5. Galvus (vildagliptin) - Novartis
    • 3.2.6. Tenelia (teneligliptin) - Daiichi Sankyo and Mitsubishi Tanabe
  • 3.3. GLP-1 Agonists
    • 3.3.1. Byetta and Bydureon (exenatide) - Bristol-Myers Squibb
    • 3.3.2. Victoza (liraglutide) - Novo Nordisk
    • 3.3.3. Lyxumia (lixisenatide) - Sanofi
  • 3.4. Sulfonylureas
    • 3.4.1. Glimepiride
    • 3.4.2. Gliclazide
  • 3.5. Thiazolidinediones
    • 3.5.1. Actos (pioglitazone) - Takeda Pharmaceuticals
  • 3.6. Long-Acting Insulins
    • 3.6.1. Lantus (insulin glargine) - Sanofi
    • 3.6.2. Levemir (insulin detemir) - Novo Nordisk
  • 3.7. SGLT Inhibitors
    • 3.7.1. Forxiga (dapagliflozin) - Bristol-Myers Squibb
    • 3.7.2. Invokana (canagliflozin) - Janssen
  • 3.8. Comparative Efficacy and Safety

4. Type 2. Diabetes Market to 2020 - Pipeline Products

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate
    • 4.4.2. Patient Enrollment and Clinical Trial Size
    • 4.4.3. Duration
  • 4.5. Promising Drug Candidates in the Pipeline
    • 4.5.1. LY-2189265 (dulaglutide) - Eli Lilly
    • 4.5.2. Albiglutide - GlaxoSmithKline
    • 4.5.3. Ipragliflozin - Astellas Pharma
    • 4.5.4. Semaglutide - Novo Nordisk

5. Market Forecast to 2020

  • 5.1. Geographical Markets
    • 5.1.1. Asia-Pacific Market
    • 5.1.2. China
    • 5.1.3. India
    • 5.1.4. Japan
    • 5.1.5. Australia
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Major Licensing Deals
    • 6.1.1. Viking Therapeutics Enters into Licensing Agreement with Ligand Pharma
    • 6.1.2. Zosano Pharma Enters into Licensing Agreement with Novo Nordisk
    • 6.1.3. Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor
    • 6.1.4. Depomed Expands Licensing Agreement with Merck for Metformin Patents
    • 6.1.5. Chugai Pharma Enters into Licensing Agreement with Kowa and Sanofi for SGLT2 Inhibitor CSG452
  • 6.2. Major Co-development Deals
    • 6.2.1. Yabao Pharma Enters into Co-Development Agreement with Eli Lilly for LY2608204
    • 6.2.2. AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb
    • 6.2.3. Isis Pharmaceuticals Enters into a Collaboration Agreement with Janssen Pharmaceuticals
    • 6.2.4. Merck Enters into Co-Development Agreement with Pfizer for Ertugliflozin

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. IND/CTA-Filed
    • 7.1.3. Preclinical
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
    • 7.1.8. Undisclosed
  • 7.2. Market Forecasts to 2019
    • 7.2.1. Global
    • 7.2.2. China
    • 7.2.3. India
    • 7.2.4. Japan
    • 7.2.5. Australia
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Type 2 Diabetes Market, Global, HbA1c and Mean Blood Glucose, 2013
  • Table 2: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (Discovery), 2014
  • Table 3: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (IND/CTA-Filed), 2014
  • Table 4: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (Preclinical), 2014
  • Table 5: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (Phase I), 2014
  • Table 6: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (Phase II), 2014
  • Table 7: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (Phase III), 2014
  • Table 8: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (Pre-registration), 2014
  • Table 9: Type 2 Diabetes Market, Global, Pharmaceutical Pipeline (Undisclosed), 2014
  • Table 10: Type 2 Diabetes Market, Asia-Pacific, Forecast Data, 2013-2020
  • Table 11: Type 2 Diabetes Market, China, Forecast Data, 2013-2020
  • Table 12: Type 2 Diabetes Market, India, Forecast Data, 2013-2020
  • Table 13: Type 2 Diabetes Market, Japan, Forecast Data, 2013-2020
  • Table 14: Type 2 Diabetes Market, Australia, Forecast Data, 2013-2020

List of Figures

  • Figure 1: Type 2 Diabetes Market, Global, Composite Treatment Algorithm, 2013
  • Figure 2: Type 2 Diabetes Market, Global, Composite Treatment Algorithm, 2013
  • Figure 3: Type 2 Diabetes Market, Global, Januvia (sitagliptin)/Janumet (sitagliptin and metformin) Annual Sales ($bn), 2007-2013
  • Figure 4: Type 2 Diabetes Market, Global, Galvus (vildagliptin) Annual Sales ($m), 2007-2013
  • Figure 5: Type 2 Diabetes Market, Global, Victoza (liraglutide) Annual Sales ($bn), 2010-2013
  • Figure 6: Type 2 Diabetes Market, Global, Lantus (insulin glargine) Annual Sales ($bn), 2007-2013
  • Figure 7: Type 2 Diabetes Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap, 2013
  • Figure 8: Type 2 Diabetes Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2014
  • Figure 9: Type 2 Diabetes Market, Global, Pipeline by Molecule Type and Stage of Development, 2014
  • Figure 10: Type 2 Diabetes Market, Global, Pipeline by Mechanism of Action, 2014
  • Figure 11: Type 2 Diabetes Market, Global, Pipeline by Mechanism of Action, 2014
  • Figure 12: Type 2 Diabetes Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development, 2014
  • Figure 13: Type 2 Diabetes Market, Global, Clinical Trial Failure Rate (%), 2014
  • Figure 14: Type 2 Diabetes Market, Global, Clinical Trial Failure Rate by Mechanism of Action (%), 2014
  • Figure 15: Type 2 Diabetes Market, Global, Clinical Trial Size, 2014
  • Figure 16: Type 2 Diabetes Market, Global, Clinical Trial Duration (months), 2014
  • Figure 17: Type 2 Diabetes Market, Asia-Pacific, Treatment Use Patterns and Market Size, 2013-2020
  • Figure 18: Type 2 Diabetes Market, China, Treatment Use Patterns, Annual Cost of Therapy ($) and Market Size, 2013-2020
  • Figure 19: Type 2 Diabetes Market, India, Treatment Use Patterns, Annual Cost of Therapy ($), and Market Size, 2013-2020
  • Figure 20: Type 2 Diabetes Market, Japan, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size, 2013-2020
  • Figure 21: Type 2 Diabetes Market, Australia, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size, 2013-2020
  • Figure 22: Type 2 Diabetes Market, Global, Deals by Value, Year and Stage of Development, 2006-2014
  • Figure 23: Type 2 Diabetes Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2014
  • Figure 24: Type 2 Diabetes Market, Global, Licensing Deals by Geography, 2006-2014
  • Figure 25: Type 2 Diabetes Market, Global, Co-development Deals by Geography, 2006-2014
  • Figure 26: GBI Research Market Forecasting Model (Example)
Back to Top